Triumvira

Triumvira Immunologics has developed the novel T Cell Antigen Coupler (TAC) technology to enhance safety and efficacy of autologous and allogeneic cell therapies for solid and hematologic malignancies. By improving upon the tumor targeting abilities of T cells in combination with the endogenous activation machinery, Triumvira aims to create a pipeline of therapies that show absence of tonic signaling, strong tumor penetration, and long-term durability of response.